This article is more than 5 years old. Information may no longer be current.
First patient dosed in phase 1/2 trial of topical anti-VEGF drop from PanOptica
Click Here to Manage Email Alerts
PanOptica has begun a phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily anti-VEGF topical eye drop formulation, the company announced in a press release.
The masked study is evaluating the new suspension formulation as monotherapy in 60 patients newly diagnosed with neovascular age-related macular degeneration. Three dose strengths will be studied for up to 3 months at sites in the United States and Europe, the release said.
“This phase 1/2 trial builds on research completed to date and advances PAN-90806 as a potentially safe and effective topical eye drop treatment for back of the eye diseases such as wet AMD and diabetic retinopathy,” Paul G. Chaney, president and CEO of PanOptica, said in the release. “Our new formulation of PAN-90806 has the potential to improve upon the safety and tolerability seen in our previous phase 1 study in patients with wet AMD and may enhance the response rate and treatment effect across a higher, broader dose range.”
The topical formulation may help reduce patients’ injection burden, thus reducing discontinuation rates and improving outcomes.